Weight Gain and Metabolic Abnormalities During Extended Risperidone Treatment in Children and Adolescents
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The aim of this study was to investigate the prevalence of clinical and laboratory metabolic abnormalities during long-term risperidone treatment in children and adolescents. METHODS: Medically healthy 7- to 17-year-old children chronically treated, in a naturalistic setting, with risperidone were recruited through child psychiatry clinics. Anthropometric measurements and laboratory testing were conducted. Developmental and medication histories were obtained from medical records. RESULTS: In 99 patients treated with risperidone for an average of 2.9 years, a significant increase in age- and gender-adjusted weight and body mass index (BMI) (i.e., z-scores) was observed. Concomitant treatment with psychostimulants did not attenuate this weight gain. Risperidone-associated weight gain was negatively correlated with the BMI z-score obtained at the onset of risperidone treatment. Compared to lean children, overweight and obese children had higher odds of metabolic abnormalities, including increased waist circumference, hypertriglyceridemia, and low high-density lipoprotein cholesterol (HDL-C). They also tended to have a higher insulin level and homeostasis model assessment insulin resistance (HOMA-IR) index. As a result, upon recruitment in the study, children with excessive weight were 12 times more likely to have at least one laboratory metabolic abnormality and seven times more likely to have at least one criterion of the metabolic syndrome compared to lean subjects. In contrast to excessive weight status, gaining > or =0.5 BMI z-score point during risperidone treatment was not associated with a significantly higher occurrence of metabolic disturbances. CONCLUSIONS: The long-term use of risperidone, especially when weight is above normal, is associated with a number of metabolic abnormalities but a low prevalence of the metabolic syndrome phenotype. Future studies should evaluate the stability of these abnormalities over time.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Variations in pattern of pubertal changes in girls
Marshall, W. A., & Tanner, J. M. (1969) · Archives of Disease in Childhood · doi:10.1136/adc.44.235.291 · Cited by 5,963
Variations in the pattern of pubertal changes in boys
Marshall, W. A., & Tanner, J. M. (1970) · Archives of Disease in Childhood · doi:10.1136/adc.45.239.13 · Cited by 5,147 · cited 1×
“Indepen-dently, the subjects, with parental help when necessary, completed a self-assessment form that included age-appropriate instructions and pictures depicting Tanner stages I through V (Marshall and Tanner 1969; Marshall and Tanner 1970).”
Cook, S., Weitzman, M., Auinger, P., Nguyen, M., & Dietz, W. H. (2003) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.157.8.821 · Cited by 2,326
The metabolic syndrome in children and adolescents ? an IDF consensus report
Zimmet, P., Alberti, K. G. M., Kaufman, F., Tajima, N., Silink, M., Arslanian, S., Wong, G., Bennett, P., Shaw, J., Caprio, S., et al. (2007) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2007.00271.x · Cited by 2,013 · cited 1×
“This issue is particularly signifi-cant because the precise definition of the metabolic syndrome in children and its long-term sequelae continue to be debated (Zimmet et al. 2007; Ford and Li 2008).”
Consensus development conference on antipsychotic drugs and obesity and diabetes
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity (2004) · Diabetes Care · doi:10.2337/diacare.27.2.596 · Cited by 1,554 · cited 5×
“W ith the dramatic increase in the use of atypical antipsychotics (AAPs) in youths over the last decade (Olfson et al. 2006), concerns have been raised regarding their safety (American Diabetes Association 2004; Correll and Carlson 2006; Newcomer and Haupt 2006).”
InfluentialRole of Nonexercise Activity Thermogenesis in Resistance to Fat Gain in Humans
Levine, J. A., Eberhardt, N. L., & Jensen, M. D. (1999) · Science · doi:10.1126/science.283.5399.212 · Cited by 997 · cited 2×
“We speculate that poorly controlled hyper-activity may have attenuated risperidone-induced weight gain due to the resultant increase in nonexercise activity thermogenesis (Levine et al. 1999).”
McGlashan, T. H., Zipursky, R. B., Perkins, D., Addington, J., Miller, T., Woods, S. W., A. Hawkins, K., E. Hoffman, R., Preda, A., Epstein, I., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.5.790 · Cited by 556 · cited 5×
“In the olanzapine trial cited earlier, no abnormalities in glucose metabolism were found (McGlashan et al. 2006), which is similar to the finding from the Spanish study comparing short-and long-term exposure to antipsychotics (Laita et al. 2007).”
InfluentialThe Analysis of Multiple Endpoints in Clinical Trials
Pocock, S. J., Geller, N. L., & Tsiatis, A. A. (1987) · Biometrics · doi:10.2307/2531989 · Cited by 524 · cited 1×
“, clinical diagnoses, pharmacotherapy, metabolic measures, and metabolic abnormalities) (Pocock et al. 1987).”
Aman, M. G., De Smedt, G., Derivan, A., Lyons, B., Findling, R. L., & Risperidone Disruptive Behavior Study Group (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.8.1337 · Cited by 475
Cited by
Correll, C. U. (2009) · JAMA · doi:10.1001/jama.2009.1549 · Cited by 1,050
“Such studies should evaluate the importance of weight change vs end point BMI for metabolic abnormalities because emerging data suggest a potentially greater importance of the latter.(32) More research is also needed to determine the time course and magnitude of developing diabetes or the metabolic syndrome and to unc…”
BackgroundThe Burden of Antipsychotic-Induced Weight Gain and Metabolic Syndrome in Children
Libowitz, M. R., & Nurmi, E. L. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.623681 · Cited by 99
Matheson, B. E., & Douglas, J. M. (2017) · Review Journal of Autism and Developmental Disorders · doi:10.1007/s40489-017-0103-7 · Cited by 81
Metadata
- Authors
- Calarge, C. A., Acion, L., Kuperman, S., Tansey, M., & Schlechte, J. A.
- Venue
- Journal of Child and Adolescent Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2009-04
- Volume
- 19
- Issue
- 2
- Pages
- 101-109
- ISSN
- 1044-5463 (ISSN-L)
- 1557-8992
- OpenAlex
- W2038823933
- Cited by
- 112
- References
- 12
- FWCI
- 5.54
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.